A. M. Chinnaiyan

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis

This study identifies NSD2 as a critical component of the AR neo-enhanceosome in prostate cancer, showing its role in AR enhancer circuitry and tumor progression.

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

This paper develops an orally bioavailable PROTAC degrader of mSWI/SNF ATPases for prostate cancer and identifies resistance mechanisms through long-term treatment.

PIKfyve controls dendritic cell function and tumor immunity

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies

This study identifies a therapeutic vulnerability in POU2F-POU2AF-driven cancers by showing that targeting the mSWI/SNF complex with a PROTAC degrader reduces tumor growth in preclinical models.

Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients

The paper compiles and provides eight scRNA-seq datasets from nine cancer types, 174 patients, and 90,270 cancer cells to study ICB treatment responses.

Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies

This paper develops humanized mouse models of metastatic prostate cancer to evaluate therapies, showing improved immune interactions and response to hormonal and immunotherapies.

Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways

The paper identifies shared molecular features between H3K27M diffuse midline gliomas and PFA ependymomas, linking them to hindbrain developmental pathways.

Multivalent proteins rapidly and reversibly phase-separate upon osmotic cell volume change

The paper shows multivalent proteins rapidly phase-separate during hyperosmotic stress and reversibly dissolve upon osmotic rescue, impacting transcription termination.

An Essential Role for Argonaute 2 in EGFR-KRAS Signaling in Pancreatic Cancer Development

This study shows AGO2 is required for pancreatic cancer progression but not initiation, with its role dependent on mutant KRAS and EGFR signaling.